Dacomitinib Versus Gefitinib in First-Line Setting for Advanced NSCLC Subgroup
Posted: Friday, November 3, 2017
A subgroup analysis of the ARCHER 1050 study found that progression-free survival with dacomitinib therapy was superior to that with gefitinib in patients with epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC). Yi-Long Wu, MD, of the Guangdon Lung Cancer Institute, Guangzhou, China, presented his group’s results at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 05.01) in Yokohama, Japan.
In this phase III, ongoing, open-label study, 452 patients with newly diagnosed stage IIIb/IV or recurrent NSCLC and EGFR-activating mutation were randomized to receive either dacomitinib or gefitinib. Patients were stratified by race and mutation subtype. In both treatment arms, 59% of patients demonstrated exon 19 deletions, and 41% of patients had L858R mutations.
Median progression-free survival in patients with exon 19 deletions was 16.5 months in the dacomitinib arm versus 9.2 months in the gefitinib arm. Patients with L858R mutations also showed higher progression-free survival when treated with dacomitinib at 12.3 months versus 9.8 months with gefitinib.
